Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosis.
Eur J Cancer
; 49(2): 411-5, 2013 Jan.
Article
em En
| MEDLINE
| ID: mdl-22980726
ABSTRACT
We describe the striking and unexpected evolution of 10 patients with de novo multiple myeloma treated with novel-agent based induction therapy, who displayed a dissociated evolution characterised by an apparent good response contrasting with the concomitant development of aggressive non-secreting plasmocytomas immediately before, or just after, autologous stem cell transplantation. Patients did not respond to salvage therapies. Eight of them died from progression less than 12 months after diagnosis. This unusual evolution in the era of novel agents warrants further scrutiny.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Terapia de Salvação
/
Mieloma Múltiplo
/
Antineoplásicos
Tipo de estudo:
Prognostic_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Eur J Cancer
Ano de publicação:
2013
Tipo de documento:
Article